Skip to main content

Pressure BioSciences Faces Delisting from Nasdaq

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences has been told by Nasdaq that it is once again in danger of having its stock delisted, the company disclosed in a document filed with the US Securities and Exchange Commission on Friday.

Pressure Bio said that on Oct. 4, Nasdaq provided written notice that the company failed to meet a listing requirement of at least $2.5 million in stockholders' equity. Nasdaq originally warned the company in April of the deficiency and possible delisting but in June the exchange extended the deadline to Oct. 3 for Pressure Bio to regain compliance.

In its SEC document, Pressure Bio said it intends to request a hearing with the Nasdaq Listing Qualifications Panel to review its determination letter received last week. Its stock will remain listing on Nasdaq until the panel renders a decision.

Pressure Bio added that it intends to present a plan to the panel at the hearing to regain compliance and to request that the panel allow the company additional time to regain compliance. The panel could give Pressure Bio 180 calendar days from Oct. 4 to do so, it said.

Pressure Bio also faces possible delisting from Nasdaq because it is not in compliance with another listing requirement that calls for a minimum bid price of $1 per share for 30 consecutive business day. The company has until Feb. 13, 2012 to regain compliance with that requirement.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.